Cargando…

Leukocytosis and presence of CALR mutation is associated with non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis

Detalles Bibliográficos
Autores principales:	Barraco, D, Lasho, T L, Gangat, N, Finke, C, Elala, Y C, Pardanani, A, Tefferi, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5141359/ https://www.ncbi.nlm.nih.gov/pubmed/27315113 http://dx.doi.org/10.1038/bcj.2016.44

Ejemplares similares

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations
por: Barraco, D, et al.
Publicado: (2016)

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations
por: Barraco, D, et al.
Publicado: (2016)

U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Non-Hepatosplenic Extramedullary Hematopoiesis Masquerading as Metastatic Malignant Melanoma
por: Williams, Aquino, et al.
Publicado: (2022)

Liver function test abnormalities and their clinical relevance in primary myelofibrosis
por: Barraco, D, et al.
Publicado: (2017)

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients
por: Cerquozzi, S., et al.
Publicado: (2017)

Genetic predictors of response to specific drugs in primary myelofibrosis
por: Penna, Domenico, et al.
Publicado: (2018)

Momelotinib therapy for myelofibrosis: a 7-year follow-up
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape
por: Tefferi, Ayalew, et al.
Publicado: (2022)

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
por: Tefferi, A, et al.
Publicado: (2012)

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML
por: Laborde, R R, et al.
Publicado: (2013)

Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
por: Tefferi, A, et al.
Publicado: (2017)

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
por: Guglielmelli, Paola, et al.
Publicado: (2023)

Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
por: Nicolosi, Maura, et al.
Publicado: (2018)

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model
por: Vallapureddy, Rangit R., et al.
Publicado: (2019)

Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
por: Tefferi, Ayalew, et al.
Publicado: (2018)

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
por: Tefferi, Ayalew, et al.
Publicado: (2018)

MPL-mutated essential thrombocythemia: a morphologic reappraisal
por: Szuber, Natasha, et al.
Publicado: (2018)

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
por: Tefferi, Ayalew, et al.
Publicado: (2023)

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis
por: Pardanani, A, et al.
Publicado: (2015)

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2013)

A case of perirenal extramedullary hematopoiesis in a patient with primary myelofibrosis
por: Imai, Kentaro, et al.
Publicado: (2017)

Extramedullary hematopoiesis in an inguinal lymph node: an unusual presentation of primary myelofibrosis
por: Yaqoob, Nausheen, et al.
Publicado: (2022)

Simultaneous hepatosplenic T-cell lymphoma and myelofibrosis
por: Gabali, Ali M, et al.
Publicado: (2014)

Definition and management of ruxolitinib treatment failure in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2014)

Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?
por: Nicolosi, Maura, et al.
Publicado: (2018)

A Case of Multifocal Extramedullary and Non-Hepatosplenic Extramedullary Hematopoiesis in a 43-Year-Old Man with a History of Congenital Eisenmenger Syndrome
por: Gawroński, Krzysztof, et al.
Publicado: (2022)

Assessment of sites of marrow and extramedullary hematopoiesis by hybrid imaging in primary myelofibrosis patients
por: Ojeda‐Uribe, Mario, et al.
Publicado: (2016)

Generalized lymphadenopathy secondary to isolated extramedullary hematopoiesis as an initial manifestation of primary myelofibrosis
por: Aljabry, Mansour S., et al.
Publicado: (2018)

Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis
por: Mudireddy, Mythri, et al.
Publicado: (2018)

Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates
por: Shah, Sahrish, et al.
Publicado: (2017)

Primary myelofibrosis with concurrent CALR and MPL mutations: A case report
por: Zhou, Feng-Ping, et al.
Publicado: (2020)

CT findings of extramedullary hematopoiesis in the thorax, liver and kidneys, in a patient with idiopathic myelofibrosis.
por: Kwak, H. S., et al.
Publicado: (2000)

Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era
por: Del Sordo, Rachele, et al.
Publicado: (2017)

Peritoneal carcinomatosis-like implants of extramedullary hematopoiesis. An insolite occurrence during splenectomy for myelofibrosis
por: Casaccia, Marco, et al.
Publicado: (2017)

MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia
por: Haider, M, et al.
Publicado: (2016)

Extramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients
por: Fan, N., et al.
Publicado: (2018)

Myelofibrosis Treatment Algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis
por: Kjær, Lasse, et al.
Publicado: (2023)

Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations
por: Barraco, D, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cd4thnj3tq5903pv65ev4jnbb4